Athletic PerformanceMg-FormNCT07640685
UCLA Magnesium Formulation Athlete Study
A study testing Magnesium glycinate and Magnesium L-threonate in people with Athletic Performance and Recovery, run by University of California, Los Angeles at 1 site in United States.
Trial summary
This randomized, double-blind, placebo-controlled trial will compare magnesium glycinate, magnesium L-threonate, and placebo in UCLA varsity athletes. Participants will complete a baseline monitoring period followed by 4 weeks of blinded nightly supplementation. Read more about this study
- Who is it for?
- Ages 18 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Athletic Performance, Recovery, Sleep
- What is being tested?
- Magnesium glycinate and Magnesium L-threonate
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 150 participants
- Where
- 1 siteUnited States
- Study dates
- 5 Oct 2026to Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age 18-35 years.
- Current NCAA Division I athlete at UCLA.
- Actively participating in team training and/or competition.
- Willing to wear a WHOOP 4.0 device continuously during the baseline and treatment periods of the study block.
- Able to swallow oral capsules and follow supplement instructions.
- Able and willing to complete daily REDCap surveys and weekly check-ins during the study block.
- Fluent in English.
- Able to provide informed consent.
Who cannot join
- Known kidney disease or impaired renal function, assessed by participant-completed screening questions and review by the PI or designated study clinician. Screening asks about known kidney disease, reduced kidney function, dialysis, a history of abnormally high magnesium, and prior medical advice to avoid magnesium supplementation. A positive or uncertain response requires clinician review. If safety cannot be established from the questionnaire and participant interview alone, the athlete will not be enrolled. The study will not access medical records or perform research laboratory testing for this screening.
- Current use of non-study magnesium supplements within the past 30 days or unwillingness to avoid non-study magnesium supplements during the study unless approved by the study clinician.
- Diagnosed or treated sleep disorder likely to confound sleep outcomes, such as untreated or unstable insomnia, sleep apnea, or regular use of sleep medication expected to affect study outcomes.
- Known difficulty swallowing capsules or history of choking.
- Known allergy or sensitivity to magnesium or inactive capsule ingredients.
- Known current pregnancy or breastfeeding, determined by participant self-report; no pregnancy testing is planned for this minimal-risk study. A participant who becomes pregnant or begins breastfeeding during the study will stop study product and notify the study team. Additional exclusionary circumstances include use of magnesium-containing laxatives or antacids during the study unless approved by the study clinician, or significant recent or planned changes in training load, diet, sleep medication, or recovery supplements that the investigator believes would confound interpretation.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Kimberly Burbank, MD contact
United States1 site, 1 recruiting
- Recruiting
University of California, Los Angeles
Los Angeles, California, 90095
Jeremy Swisher, MD, 936-520-3595, jswisher@mednet.ucla.edu
Kimberly Burbank, MD, kburbank@mednet.ucla.edu
About this study
Official title: Effects of Magnesium Glycinate and Magnesium L-Threonate on Sleep, Recovery, and Performance in Collegiate Athletes
This randomized, double-blind, placebo-controlled trial will compare magnesium glycinate, magnesium L-threonate, and placebo in UCLA varsity athletes. Participants will complete a baseline monitoring period followed by 4 weeks of blinded nightly supplementation. WHOOP 4.0 data will be used to evaluate sleep efficiency, total sleep time, sleep consistency, heart rate variability, resting heart rate, and recovery metrics. Baseline and final testing will assess selected reaction and physical performance outcomes. The primary outcome is change in WHOOP-derived sleep efficiency from baseline week to final treatment week.
Read the detailed description
Magnesium is involved in neuromuscular signaling, cellular energy metabolism, autonomic regulation, and sleep-related physiology. Competitive athletes often experience sleep restriction, training stress, travel, soreness, and recovery demands. Magnesium glycinate and magnesium L-threonate are commonly used athlete-facing magnesium formulations, but they are not interchangeable. Glycinate is commonly positioned as a well-tolerated sleep-oriented formulation, whereas L-threonate is of interest because of prior signals related to sleep, cognition, reaction performance, and central nervous system magnesium biology. This single-site UCLA study will enroll adult varsity athletes aged 18 to 35 years. Participants will complete screening, informed consent, baseline assessments, wearable monitoring, a baseline monitoring period, randomization in a 1:1:1 ratio, 4 weeks of blinded nightly capsules, brief daily REDCap morning surveys, weekly adherence and safety check-ins, and final performance-adjacent testing. The primary outcome is change in average WHOOP-derived sleep efficiency from baseline week to final treatment week. Prespecified primary contrasts will compare magnesium glycinate versus placebo and magnesium L-threonate versus placebo. Total sleep time, sleep consistency, resting heart rate, heart rate variability, WHOOP Recovery Score, reaction-time performance, grip strength, countermovement jump height, adherence, tolerability, and adverse events will be analyzed as secondary or exploratory outcomes according to the final statistical analysis plan. The magnesium glycinate versus magnesium L-threonate contrast will be treated as exploratory unless the final statistical analysis plan preserves alpha for that comparison.
- Conditions
- Athletic Performance, Recovery, Sleep
- Being tested
- Magnesium glycinate, Magnesium L-threonate, Placebo
- Keywords
- magnesium glycinate, magnesium L-threonate, collegiate athletes, sleep duration, athlete recovery, WHOOP, heart rate variability, reaction time, placebo-controlled trial, dietary supplement
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Magnesium glycinateDietary supplement
Blinded oral magnesium glycinate, exactly two capsules nightly for 28 days. The nightly dose is 240 mg elemental magnesium by label claim (120 mg per capsule) and 288 mg by lot-specific assay (144 mg per capsule). Take approximately 1 hour before intended bedtime, with food, while upright, and with at least 8 oz water. No study product is taken during the 1-week baseline period.
Magnesium L-threonateDietary supplement
Blinded oral magnesium L-threonate (Magtein), exactly two 1-g capsules nightly for 28 days, for 2 g Magtein and 156 mg elemental magnesium nightly based on the linked raw-ingredient assay of 7.8% magnesium. Take approximately 1 hour before intended bedtime, with food, while upright, and with at least 8 oz water. No study product is taken during the 1-week baseline period.
PlaceboOther
Matched oral placebo, exactly two capsules nightly for 28 days. Each capsule contains calcium laurate 300 mg plus silicified microcrystalline cellulose 440 mg and no active magnesium. Take approximately 1 hour before intended bedtime, with food, while upright, and with at least 8 oz water. No study product is taken during the 1-week baseline period. One matched-placebo regimen is used, without double-dummy.
| Study group | Role | What they receive |
|---|---|---|
| Magnesium Glycinate | Experimental | Participants randomized to this arm will take exactly two blinded magnesium glycinate capsules nightly for 4 weeks (28 days). Each capsule is labeled to provide 120 mg elemental magnesium, for 240 mg by label claim nightly; the lot-specific assay reports 144 mg per capsule, for 288 mg by assay nightly. The capsules are clear/natural size 00-EL HPMC capsules containing white powder. Take the two capsules approximately 1 hour before intended bedtime, with food, while upright, and with at least 8 oz water. There is no study product during the 1-week baseline period. Receives: Dietary Supplement: Magnesium glycinate |
| Magnesium L-Threonate | Experimental | Participants randomized to this arm will take exactly two blinded capsules containing 1 g Magtein (magnesium L-threonate) each nightly for 4 weeks (28 days), for 2 g Magtein nightly. This corresponds to 156 mg elemental magnesium nightly based on the linked raw-ingredient certificate of analysis reporting 7.8% magnesium. The capsules are clear/natural size 00-EL HPMC capsules containing white powder. Take the two capsules approximately 1 hour before intended bedtime, with food, while upright, and with at least 8 oz water. There is no study product during the 1-week baseline period. Receives: Dietary Supplement: Magnesium L-threonate |
| Placebo | Placebo comparator | Participants randomized to this arm will take exactly two matched placebo capsules nightly for 4 weeks (28 days). Each capsule contains calcium laurate 300 mg plus silicified microcrystalline cellulose 440 mg and no active magnesium. The capsules are clear/natural size 00-EL HPMC capsules containing white powder. Take the two capsules approximately 1 hour before intended bedtime, with food, while upright, and with at least 8 oz water. There is no study product during the 1-week baseline period. The study uses one matched-placebo regimen and no double-dummy design. Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in WHOOP-derived sleep efficiency percentage from baseline week to final treatment week
Average nightly WHOOP-derived sleep efficiency, expressed as a percentage, will be calculated for the baseline week and final treatment week. A valid week requires at least 5 usable nights in the 7-day window. The outcome is final-treatment-week average minus baseline-week average; higher values indicate improved sleep efficiency.
Measured: Baseline week to final treatment week, approximately 5 weeks total including baseline monitoring
Secondary outcomes (10)
Change in BlazePod RIW Challenge reaction time in milliseconds from baseline to final visit
Reaction performance will be measured using the prespecified BlazePod RIW Challenge protocol. The outcome is change in reaction time in milliseconds from baseline to final visit. Lower reaction time indicates better performance.
Measured: Baseline to final visit, approximately 5 weeks
Change in BlazePod Speed Tap reaction time in milliseconds from baseline to final visit
Reaction performance will be measured using the prespecified BlazePod Speed Tap protocol. The outcome is change in reaction time in milliseconds from baseline to final visit. Lower reaction time indicates better performance.
Measured: Baseline to final visit, approximately 5 weeks
Change in WHOOP-derived sleep consistency score from baseline week to final treatment week
WHOOP 4.0-derived sleep consistency score, or an equivalent prespecified WHOOP 4.0-derived sleep timing regularity metric, will be summarized for the baseline week and final treatment week. The outcome is final-treatment-week average minus baseline-week average.
Measured: Baseline week to final treatment week, approximately 5 weeks total including baseline monitoring
Change in WHOOP-derived total sleep time in minutes from baseline week to final treatment week
Average nightly total sleep time captured by WHOOP, expressed in minutes, will be calculated for the baseline week and final treatment week. The outcome is final-treatment-week average minus baseline-week average.
Measured: Baseline week to final treatment week, approximately 5 weeks total including baseline monitoring
Change in WHOOP-derived resting heart rate in beats per minute from baseline week to final treatment week
Nightly resting heart rate captured by WHOOP, expressed in beats per minute, will be summarized as weekly averages for the baseline week and final treatment week. The outcome is final-treatment-week average minus baseline-week average.
Measured: Baseline week to final treatment week, approximately 5 weeks total including baseline monitoring
Change in WHOOP-derived heart rate variability in milliseconds from baseline week to final treatment week
Nightly heart rate variability captured by WHOOP, expressed in milliseconds, will be summarized as weekly averages for the baseline week and final treatment week. The outcome is final-treatment-week average minus baseline-week average.
Measured: Baseline week to final treatment week, approximately 5 weeks total including baseline monitoring
Change in WHOOP Recovery Score from baseline week to final treatment week
WHOOP Recovery Score, reported on a 0 to 100 scale where higher scores indicate better recovery, will be summarized as weekly averages for the baseline week and final treatment week. The outcome is final-treatment-week average minus baseline-week average.
Measured: Baseline week to final treatment week, approximately 5 weeks total including baseline monitoring
Change in VALD dynamometer bilateral average handgrip strength from baseline to final visit
Bilateral average handgrip strength will be measured with the prespecified VALD handgrip dynamometer protocol. The outcome is final-visit bilateral average handgrip strength minus baseline bilateral average handgrip strength.
Measured: Baseline to final visit, approximately 5 weeks
Change in VALD force plate countermovement jump height from baseline to final visit
Countermovement jump height will be measured with the prespecified VALD force plate protocol. The outcome is final-visit jump height minus baseline jump height.
Measured: Baseline to final visit, approximately 5 weeks
Number of participants with adverse events and supplement tolerability concerns
The number of participants with adverse events, tolerability concerns, dose interruptions, and study-product discontinuations will be summarized by study arm. Events of interest include gastrointestinal symptoms, sedation, dizziness, headache, allergic reaction, skin irritation from wearable use, and study-product discontinuation.
Measured: From first dose through final visit, approximately 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2026
- Study start5 Oct 2026
- Primary completionMay 2027 (estimated)
- Study completionJun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Athletic PerformanceStudies of the same condition, open and under way.
- More trials run by University of California, Los AngelesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomized in a 1:1:1 ratio to magnesium glycinate, magnesium L-threonate, or placebo.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, Los Angeles
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jeremy Swisher, MD, University of California, Los Angeles
- Investigators
- Jeremy Swisher, MD, Principal investigator, University of California, Los AngelesJoshua Goldman, MD, Study director, University of California, Los Angeles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07640685
- Sponsor's protocol ID
- IRB-26-1185
- Acronym
- Mg-Form
- Status last verified
- Oct 2026
- First submitted
- 26 May 2026
- Last updated
- 15 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No individual participant data sharing is planned because the study involves a relatively small cohort of collegiate athletes and individual-level sleep, recovery, performance, and sport-related data may create re-identification risk. Aggregate results may be disseminated through presentations, manuscripts, and ClinicalTrials.gov summaries as applicable.
Publications
Hausenblas HA, Lynch T, Hooper S, Shrestha A, Rosendale D, Gu J. Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems: A randomized controlled trial. Sleep Med X. 2024 Aug 17;8:100121. doi: 10.1016/j.sleepx.2024.100121. eCollection 2024 Dec 15.
PubMed 39252819Schuster J, Cycelskij I, Lopresti A, Hahn A. Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial. Nat Sci Sleep. 2025 Aug 30;17:2027-2040. doi: 10.2147/NSS.S524348. eCollection 2025.
PubMed 40918053Mah J, Pitre T. Oral magnesium supplementation for insomnia in older adults: a Systematic Review & Meta-Analysis. BMC Complement Med Ther. 2021 Apr 17;21(1):125. doi: 10.1186/s12906-021-03297-z.
PubMed 33865376Walsh NP, Halson SL, Sargent C, Roach GD, Nedelec M, Gupta L, Leeder J, Fullagar HH, Coutts AJ, Edwards BJ, Pullinger SA, Robertson CM, Burniston JG, Lastella M, Le Meur Y, Hausswirth C, Bender AM, Grandner MA, Samuels CH. Sleep and the athlete: narrative review and 2021 expert consensus recommendations. Br J Sports Med. 2020 Nov 3:bjsports-2020-102025. doi: 10.1136/bjsports-2020-102025. Online ahead of print.
PubMed 33144349Miller DJ, Lastella M, Scanlan AT, Bellenger C, Halson SL, Roach GD, Sargent C. A validation study of the WHOOP strap against polysomnography to assess sleep. J Sports Sci. 2020 Nov;38(22):2631-2636. doi: 10.1080/02640414.2020.1797448. Epub 2020 Jul 26.
PubMed 32713257Gupta L, Morgan K, Gilchrist S. Does Elite Sport Degrade Sleep Quality? A Systematic Review. Sports Med. 2017 Jul;47(7):1317-1333. doi: 10.1007/s40279-016-0650-6.
PubMed 27900583
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Magnesium Glycinate and Magnesium L-Threonate on Sleep, Recovery, and Performance in Collegiate Athletes
- ClinicalTrials.gov ID
- NCT07640685
- Acronym / sponsor ID
- Mg-Form / IRB-26-1185
- Conditions
- Athletic Performance, Recovery, Sleep
- Keywords
- magnesium glycinate, magnesium L-threonate, collegiate athletes, sleep duration, athlete recovery, WHOOP, heart rate variability, reaction time
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- University of California, Los AngelesUniversity, hospital or other
- Study start
- 5 Oct 2026 (actual)
- Primary completion
- May 2027 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 11 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized, double-blind, placebo-controlled trial will compare magnesium glycinate, magnesium L-threonate, and placebo in UCLA varsity athletes. Participants will complete a baseline monitoring period followed by 4 weeks of blinded nightly supplementation. WHOOP 4.0 data will be used to evaluate sleep efficiency, total sleep time, sleep consistency, heart rate variability, resting heart rate, and recovery metrics. Baseline and final testing will assess selected reaction and physical performance outcomes. The primary outcome is change in WHOOP-derived sleep efficiency from baseline week to final treatment week.
Detailed description
Magnesium is involved in neuromuscular signaling, cellular energy metabolism, autonomic regulation, and sleep-related physiology. Competitive athletes often experience sleep restriction, training stress, travel, soreness, and recovery demands. Magnesium glycinate and magnesium L-threonate are commonly used athlete-facing magnesium formulations, but they are not interchangeable. Glycinate is commonly positioned as a well-tolerated sleep-oriented formulation, whereas L-threonate is of interest because of prior signals related to sleep, cognition, reaction performance, and central nervous system magnesium biology. This single-site UCLA study will enroll adult varsity athletes aged 18 to 35 years. Participants will complete screening, informed consent, baseline assessments, wearable monitoring, a baseline monitoring period, randomization in a 1:1:1 ratio, 4 weeks of blinded nightly capsules, brief daily REDCap morning surveys, weekly adherence and safety check-ins, and final performance-adjacent testing. The primary outcome is change in average WHOOP-derived sleep efficiency from baseline week to final treatment week. Prespecified primary contrasts will compare magnesium glycinate versus placebo and magnesium L-threonate versus placebo. Total sleep time, sleep consistency, resting heart rate, heart rate variability, WHOOP Recovery Score, reaction-time performance, grip strength, countermovement jump height, adherence, tolerability, and adverse events will be analyzed as secondary or exploratory outcomes according to the final statistical analysis plan. The magnesium glycinate versus magnesium L-threonate contrast will be treated as exploratory unless the final statistical analysis plan preserves alpha for that comparison.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- Participants will be randomized in a 1:1:1 ratio to magnesium glycinate, magnesium L-threonate, or placebo.
| Arm | Type | Receives |
|---|---|---|
| Magnesium Glycinate | Experimental | Dietary Supplement: Magnesium glycinateParticipants randomized to this arm will take exactly two blinded magnesium glycinate capsules nightly for 4 weeks (28 days). Each capsule is labeled to provide 120 mg elemental magnesium, for 240 mg by label claim nightly; the lot-specific assay reports 144 mg per capsule, for 288 mg by assay nightly. The capsules are clear/natural size 00-EL HPMC capsules containing white powder. Take the two capsules approximately 1 hour before intended bedtime, with food, while upright, and with at least 8 oz water. There is no study product during the 1-week baseline period. |
| Magnesium L-Threonate | Experimental | Dietary Supplement: Magnesium L-threonateParticipants randomized to this arm will take exactly two blinded capsules containing 1 g Magtein (magnesium L-threonate) each nightly for 4 weeks (28 days), for 2 g Magtein nightly. This corresponds to 156 mg elemental magnesium nightly based on the linked raw-ingredient certificate of analysis reporting 7.8% magnesium. The capsules are clear/natural size 00-EL HPMC capsules containing white powder. Take the two capsules approximately 1 hour before intended bedtime, with food, while upright, and with at least 8 oz water. There is no study product during the 1-week baseline period. |
| Placebo | Placebo comparator | Other: PlaceboParticipants randomized to this arm will take exactly two matched placebo capsules nightly for 4 weeks (28 days). Each capsule contains calcium laurate 300 mg plus silicified microcrystalline cellulose 440 mg and no active magnesium. The capsules are clear/natural size 00-EL HPMC capsules containing white powder. Take the two capsules approximately 1 hour before intended bedtime, with food, while upright, and with at least 8 oz water. There is no study product during the 1-week baseline period. The study uses one matched-placebo regimen and no double-dummy design. |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Age 18-35 years.
- Current NCAA Division I athlete at UCLA.
- Actively participating in team training and/or competition.
- Willing to wear a WHOOP 4.0 device continuously during the baseline and treatment periods of the study block.
- Able to swallow oral capsules and follow supplement instructions.
Key exclusion criteria (6 listed)
- Known kidney disease or impaired renal function, assessed by participant-completed screening questions and review by the PI or designated study clinician. Screening asks about known kidney disease, reduced kidney function, dialysis, a history of abnormally high magnesium, and prior medical advice to avoid magnesium supplementation. A positive or uncertain response requires clinician review. If safety cannot be established from the questionnaire and participant interview alone, the athlete will not be enrolled. The study will not access medical records or perform research laboratory testing for this screening.
- Current use of non-study magnesium supplements within the past 30 days or unwillingness to avoid non-study magnesium supplements during the study unless approved by the study clinician.
- Diagnosed or treated sleep disorder likely to confound sleep outcomes, such as untreated or unstable insomnia, sleep apnea, or regular use of sleep medication expected to affect study outcomes.
- Known difficulty swallowing capsules or history of choking.
- Known allergy or sensitivity to magnesium or inactive capsule ingredients.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Magnesium glycinateBlinded oral magnesium glycinate, exactly two capsules nightly for 28 days. The nightly dose is 240 mg elemental magnesium by label claim (120 mg per capsule) and 288 mg by lot-specific assay (144 mg per capsule). Take approximately 1 hour before intended bedtime, with food, while upright, and with at least 8 oz water. No study product is taken during the 1-week baseline period. | Dietary supplement | Magnesium Glycinate |
| Magnesium L-threonateBlinded oral magnesium L-threonate (Magtein), exactly two 1-g capsules nightly for 28 days, for 2 g Magtein and 156 mg elemental magnesium nightly based on the linked raw-ingredient assay of 7.8% magnesium. Take approximately 1 hour before intended bedtime, with food, while upright, and with at least 8 oz water. No study product is taken during the 1-week baseline period. | Dietary supplement | Magnesium L-Threonate |
| PlaceboMatched oral placebo, exactly two capsules nightly for 28 days. Each capsule contains calcium laurate 300 mg plus silicified microcrystalline cellulose 440 mg and no active magnesium. Take approximately 1 hour before intended bedtime, with food, while upright, and with at least 8 oz water. No study product is taken during the 1-week baseline period. One matched-placebo regimen is used, without double-dummy. | Other | Placebo |
Primary outcome
Change in WHOOP-derived sleep efficiency percentage from baseline week to final treatment week
Time frame: Baseline week to final treatment week, approximately 5 weeks total including baseline monitoring
Average nightly WHOOP-derived sleep efficiency, expressed as a percentage, will be calculated for the baseline week and final treatment week. A valid week requires at least 5 usable nights in the 7-day window. The outcome is final-treatment-week average minus baseline-week average; higher values indicate improved sleep efficiency.
10 secondary outcomes
Change in BlazePod RIW Challenge reaction time in milliseconds from baseline to final visit
Time frame: Baseline to final visit, approximately 5 weeks
Change in BlazePod Speed Tap reaction time in milliseconds from baseline to final visit
Time frame: Baseline to final visit, approximately 5 weeks
Change in WHOOP-derived sleep consistency score from baseline week to final treatment week
Time frame: Baseline week to final treatment week, approximately 5 weeks total including baseline monitoring
Change in WHOOP-derived total sleep time in minutes from baseline week to final treatment week
Time frame: Baseline week to final treatment week, approximately 5 weeks total including baseline monitoring
Change in WHOOP-derived resting heart rate in beats per minute from baseline week to final treatment week
Time frame: Baseline week to final treatment week, approximately 5 weeks total including baseline monitoring
Change in WHOOP-derived heart rate variability in milliseconds from baseline week to final treatment week
Time frame: Baseline week to final treatment week, approximately 5 weeks total including baseline monitoring
Change in WHOOP Recovery Score from baseline week to final treatment week
Time frame: Baseline week to final treatment week, approximately 5 weeks total including baseline monitoring
Change in VALD dynamometer bilateral average handgrip strength from baseline to final visit
Time frame: Baseline to final visit, approximately 5 weeks
Change in VALD force plate countermovement jump height from baseline to final visit
Time frame: Baseline to final visit, approximately 5 weeks
Number of participants with adverse events and supplement tolerability concerns
Time frame: From first dose through final visit, approximately 4 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2026.
- Background: PubMed 39252819Hausenblas HA, Lynch T, Hooper S, Shrestha A, Rosendale D, Gu J. Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems: A randomized controlled trial. Sleep Med X. 2024 Aug 17;8:100121. doi: 10.1016/j.sleepx.2024.100121. eCollection 2024 Dec 15.
- Background: PubMed 40918053Schuster J, Cycelskij I, Lopresti A, Hahn A. Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial. Nat Sci Sleep. 2025 Aug 30;17:2027-2040. doi: 10.2147/NSS.S524348. eCollection 2025.
- Background: PubMed 33865376Mah J, Pitre T. Oral magnesium supplementation for insomnia in older adults: a Systematic Review & Meta-Analysis. BMC Complement Med Ther. 2021 Apr 17;21(1):125. doi: 10.1186/s12906-021-03297-z.
- Background: PubMed 33144349Walsh NP, Halson SL, Sargent C, Roach GD, Nedelec M, Gupta L, Leeder J, Fullagar HH, Coutts AJ, Edwards BJ, Pullinger SA, Robertson CM, Burniston JG, Lastella M, Le Meur Y, Hausswirth C, Bender AM, Grandner MA, Samuels CH. Sleep and the athlete: narrative review and 2021 expert consensus recommendations. Br J Sports Med. 2020 Nov 3:bjsports-2020-102025. doi: 10.1136/bjsports-2020-102025. Online ahead of print.
- Background: PubMed 32713257Miller DJ, Lastella M, Scanlan AT, Bellenger C, Halson SL, Roach GD, Sargent C. A validation study of the WHOOP strap against polysomnography to assess sleep. J Sports Sci. 2020 Nov;38(22):2631-2636. doi: 10.1080/02640414.2020.1797448. Epub 2020 Jul 26.
- Background: PubMed 27900583Gupta L, Morgan K, Gilchrist S. Does Elite Sport Degrade Sleep Quality? A Systematic Review. Sports Med. 2017 Jul;47(7):1317-1333. doi: 10.1007/s40279-016-0650-6.
- Individual participant dataSharing planned: No. No individual participant data sharing is planned because the study involves a relatively small cohort of collegiate athletes and individual-level sleep, recovery, performance, and sport-related data may create re-identification risk. Aggregate results may be disseminated through presentations, manuscripts, and ClinicalTrials.gov summaries as applicable.
Related trials for Athletic Performance
Active, not recruiting
Effects of Blood Flow Restriction Training on Physical Function, Muscle Adaptations, and Performance in Roller Skaters
Athletic Performance Enhancement
Not yet recruiting
Delayed Morning Training, Sleep, and Change-of-Direction Performance in Badminton Athletes
Sleep Duration, Athletic Performance
Active, not recruitingObservational study
Physiological and Performance Characteristics of HYROX Athletes
Physical Fitness, Athletic Performance
Active, not recruiting
Weighted-Vest Versus Bodyweight Plyometric Training in Youth Female Soccer Players
Healthy, Athletic Performance
Not yet recruiting
A Multiphase Analysis of Next-generation Trail Footwear
Running, Athletic Performance
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Kimberly Burbank, MD contact
Jeremy Swisher, MD principal investigator
University of California, Los Angeles
Joshua Goldman, MD study director
University of California, Los Angeles
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Magnesium glycinate and Magnesium L-threonate in people with Athletic Performance and Recovery, run by University of California, Los Angeles at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jeremy Swisher, MD (936-520-3595, jswisher@mednet.ucla.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in WHOOP-derived sleep efficiency percentage from baseline week to final treatment week (time frame: Baseline week to final treatment week, approximately 5 weeks total including baseline monitoring). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07640685, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026; AzTrials last refreshed its copy on 27 Oct 2026.